Knee Replacement Surgery Market worth $16.17 billion in 2030

 The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$16.17 billion by the end of the period. The key factor propelling the market is the increasing prevalence of osteoarthritis, particularly among the aging population. This increase in cases is driving a higher demand for surgical interventions, including total and partial knee replacements. As life expectancy increases and age-associated degenerative changes to the knee joint become more pronounced, the necessity for these procedures is escalating. This demographic shift is a significant catalyst for market expansion, contributing to a growing global patient population requiring knee treatment solutions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=246869535

The orthobiologics segment is expected to register a significant growth rate over the forecast period.

Based on the product, the global knee replacement surgery market is segmented into knee implants, knee braces & support systems, and orthobiologics. The orthobiologics segment is expected to register significant growth over the forecast period. A growing number of patients are opting for non-surgical interventions to manage their conditions. Orthobiologics, such as Platelet-Rich Plasma (PRP) therapy, stem cell treatments, and hyaluronic acid injections, provide less invasive alternatives that enhance healing and stimulate tissue regeneration. These modalities are particularly beneficial for patients with early to moderate osteoarthritis, where conventional surgical interventions may be premature or unnecessary.

Rheumatoid arthritis & osteoarthritis are expected to register higher CAGR during the study period.

By application, the global knee replacement surgery market is segmented into osteoarthritis & rheumatoid arthritis, degenerative disease, cancer, and other applications. The Centers for Disease Control and Prevention (CDC) reports that approximately 319,000 individuals aged 65 and older are hospitalized annually in the United States due to hip fractures. Surgical intervention typically involves the use of fixation devices that stabilize the fractured bone by immobilizing it, thereby providing a protective framework that facilitates healing. The incorporation of orthobiologics into orthopedic procedures is gaining traction, as these biological agents enhance the regenerative capacity of tissues and promote faster recovery. With the increasing prevalence of conditions such as rheumatoid arthritis and osteoarthritis, coupled with a growing geriatric population, there is a projected surge in the adoption of knee surgery devices to address these joint pathologies effectively.

The hospitals segment commanded the alargest end user market share in 2024.

The end user segment of the knee replacement surgery market includes hospitals, ambulatory surgery centers, and orthopedic clinics. In 2024, hospitals accounted for the largest market share. Recent advancements in surgical technologies, anesthesia techniques, and shifts in Medicare reimbursement policies have driven an escalation in orthopedic procedures within outpatient environments, particularly ambulatory surgery centers. These developments are poised to significantly enhance the expansion of the ASC market. Consequently, we can anticipate a marked increase in the volume of knee arthroplasties conducted in these settings, thereby further propelling the growth of the ASC segment in the near future. As of 2024, prominent players in the knee replacement surgery market are Zimmer Biomet (US), Stryker (US), Johnson & Johnson, Inc. (US), Smith+Nephew PLC (UK), and B. Braun (Germany).

RECENT DEVELOPMENTS

  • January 2025 : Zimmer Biomet and Paragon 28 entered into a definitive agreement for Zimmer Biomet to acquire all shares of Paragon 28
  • September 2024 : Stryker (US) acquired Care.ai to deliver ambient intelligence solutions, smart room technologies, and AI-assisted virtual care processes.
  • July 2024 : Smith+Nephew (UK) partnered with Healthcare Outcomes Performance Company. This deal focused on enhanced solutions for healthcare professionals, patients, and ASCs via their platform.
  • June 2024 : Zimmer Biomet (US) announced a distribution agreement with THINK Surgical. Zimmer Biomet tech will be incorporated with the TMNII robotic solution by THINK Surgical.
  • March 2024 : Stryker (US) acquired SERF SAS to expand its European presence and strengthen its implant product line

For more information, Inquire Now!

Comments

Popular posts from this blog

Adhesion Barrier Industry worth $0.9 billion by 2028, with a CAGR of 7.4%

Exploring the Versatile Uses of Liquid Biopsies in Modern Medicine

Exploring the Impact of Animal Genetics Testing: Revolutionizing Animal Breeding and Health